Vascular Endothelial Growth Factors
"Vascular Endothelial Growth Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.
| Descriptor ID |
D042442
|
| MeSH Number(s) |
D12.644.276.100.800 D12.776.467.100.800 D23.529.100.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factors".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factors".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factors" by people in this website by year, and whether "Vascular Endothelial Growth Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 10 | 10 |
| 1999 | 0 | 17 | 17 |
| 2000 | 0 | 28 | 28 |
| 2001 | 0 | 35 | 35 |
| 2002 | 0 | 44 | 44 |
| 2003 | 0 | 19 | 19 |
| 2004 | 3 | 1 | 4 |
| 2005 | 3 | 1 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 3 | 1 | 4 |
| 2013 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factors" by people in Profiles.
-
Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization. Biomolecules. 2024 Feb 21; 14(3).
-
Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023 06; 8(1).
-
Notch1 signaling in keratocytes maintains corneal transparency by suppressing VEGF expression. Stem Cell Reports. 2022 06 14; 17(6):1442-1457.
-
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. Am Heart J. 2021 11; 241:38-49.
-
miR-18a Inhibits BMP4 and HIF-1a Normalizing Brain Arteriovenous Malformations. Circ Res. 2020 10 09; 127(9):e210-e231.
-
Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386.
-
tmem33 is essential for VEGF-mediated endothelial calcium oscillations and angiogenesis. Nat Commun. 2019 02 13; 10(1):732.
-
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016 10 11; 115(8):974-982.
-
Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemother Pharmacol. 2013 Jul; 72(1):1-12.
-
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013.